SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                   FORM 10QSB


                  Quarterly Report under Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


For Quarter Ended                           Commission File Number
-----------------                           ----------------------
September 30, 2001                                  000-28519




                                   ATNG, INC.
                            -------------------------
                                   (New Name)


                         PATHOBIOTEK DIAGNOSTICS, INC.
                        -------------------------------
                                 (Former Name)


               Texas                        76-0510754
               -------                      ----------
        (State of incorporation)            (I.R.S. Employer
                                            Identification No.)

            4800 Research Forest Drive, The Woodlands, TX 77381-4142
            ----------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (901) 818-4880


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2)  has  been  subject  to the  filing
requirements for at least the past 90 days.

                                Yes  X     No
                                   -----     -----

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date.

                 390,696 common shares as of September 30, 2001


<PAGE>



Part I:  FINANCIAL INFORMATION

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)

<PAGE>
<TABLE>
<CAPTION>
PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET (UNAUDITED)

                                                                             September 30, 2001                 December 31, 1999
                                                                          --------------------------         -----------------------
<S>                                                                     <C>                                  <C>
ASSETS
CURRENT ASSETS
    Cash and cash equivalents                                                         -                      $     5,115
    Employee receivables                                                $         2,158                            2,158
    Due from lender                                                             239,794                                -
                                                                          --------------                     ------------
Total current assets                                                            241,952                            7,273

PROPERTY AND EQUIPMENT, at cost                                                 145,366                          143,533
    Less: Accumulated depreciation                                             (114,215)                         (93,496)
                                                                          --------------                     ------------
                                                                                 31,151                           49,037

OTHER ASSETS
    Deposits                                                                     10,000                           10,000
    Patent costs                                                                 59,459                           59,459
    Less: Accumulated amortization                                              (11,339)                          (8,799)
    Other assets                                                                    300                              300
                                                                          --------------                     ------------
                                                                                 58,420                           60,960
                                                                          --------------                     ------------
                                                                        $       331,522                         $117,270
                                                                          ==============                     ============

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
    Cash overdraft                                                      $         8,432                      $         -
    Trade accounts payable and accrued expenses                                 454,724                          314,868
    Due to shareholder                                                           26,361                           28,150
    Notes payable                                                               270,000                                -
                                                                          --------------                     ------------
Total current liabilities                                                       759,516                          343,018

SHAREHOLDERS' EQUITY
    Common stock, $.001 par value,
      authorized 20,000,000 shares,
      issued and outstanding 14,163,520 shares,
      stock suscribed but not issued 1,464,283 shares
      (Note 6)                                                                   15,628                           15,348
    Additional paid in capital                                                1,857,017                        1,766,672
    Deficit accumulated during the development stage                         (2,300,639)                      (2,007,768)
                                                                          --------------                     ------------
Total shareholders' equity                                                     (427,994)                        (225,748)
                                                                          --------------                     ------------
                                                                        $       331,522                      $   117,270
                                                                          ==============                     ============
</TABLE>


See notes to financial statements.

                                      F-1


<PAGE>

<TABLE>
<CAPTION>


PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT (UNAUDITED)







                                                    Nine               Nine           Three            Three           From
                                                   months             months          months          months       August 5, 1996
                                                   ended              ended           ended            ended          through
                                               Sept. 30, 2001     Sept. 30, 2000  Sept. 30, 2001   Sept. 30, 2000  Sept. 30, 2001
                                             -------------------  --------------- ---------------  --------------  --------------
<S>                                                  <C>       <C>                    <C>        <C>             <C>
Revenues                                                      0 $              0               0 $             0 $         1,850
Direct costs                                                  0                0               0               0               0
                                             -------------------  --------------- ---------------  --------------  --------------
Gross profit                                                  0                0               0               0           1,850

Administrative and general expenses                     268,640          660,052          68,335         164,780       2,154,713
Depreciation and amortization expense                    23,261           18,875           7,815           6,735         125,554
                                             -------------------  --------------- ---------------  --------------  --------------
                                                        291,901          678,927          76,150         171,515       2,280,267
                                             -------------------  --------------- ---------------  --------------  --------------
Loss from operations                                   (291,901)        (678,927)        (76,150)       (171,515)     (2,278,417)

Other income                                                  0                0               0                           4,800
Interest expense                                           (970)          (2,499)              0            (425)        (27,022)
                                             -------------------  --------------- ---------------  --------------  --------------
                                                           (970)          (2,499)              0            (425)        (22,222)
                                             -------------------  --------------- ---------------  --------------  --------------
Loss before income taxes                               (292,871)        (681,426)        (76,150)       (171,940)     (2,300,639)
Federal income taxes - current expense (benefit)              0                0               0               0               0
                                             -------------------  --------------- ---------------  --------------  --------------
Net loss                                               (292,871)        (681,426)        (76,150)       (171,940)     (2,300,639)

Accumulated deficit at beginning of period           (2,007,768)      (2,370,418)     (2,224,489)     (2,879,904)              0
                                             -------------------  --------------- ---------------  --------------  --------------
Deficit accumulated during the development stage     (2,300,639)$     (3,051,844)     (2,300,639)$    (3,051,844)$    (2,300,639)
                                             ===================  =============== ===============  ==============  ==============
Loss Per Share                                             (.02)            (.05)           (.01)           (.01)

</TABLE>


See notes to financial statements.

                                      F-2

<PAGE>

<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED)
For the Period August 5, 1996 (Inception) through September 30, 2001
                                                                                                             Deficit
                                                                                                            Accumulated
                                                                                            Additional     During the
                                                                 Common                       Paid in       Development
                                                                  Stock                     Capital (3)       Stage         Total
                                                             ----------------------------------------------------------------------
<S>                                                             <C>              <C>       <C>            <C>         <C>
Issuance of 4,000,000 shares - August 7, 1996                    4,000,000 (1)   $   4,000 $              $           $      4,000
Issuance of 77,320 shares - January 23, 1997                        77,320              77         9,923                    10,000
Issuance of 300,000 shares - January 23, 1997                      300,000 (2)         300                                     300
Issuance of 86,800 shares - Various dates in 1997                   86,800              87        35,118                    35,205
Issuance of 480,000 shares - Various dates in 1997                 480,000             480       254,520                   255,000
Net loss for the period August 5, 1996 (Inception) through
     July 31, 1997                                                                                           (325,680)    (325,680)
                                                             ----------------------------------------------------------------------
Balance at July 31, 1997                                         4,944,120           4,944       299,561     (325,680)     (21,175)
Issuance of 970,193 shares - Various dates in 1998                 970,193             970       417,927                   418,897
Repurchase of 225,000 shares - Various dates in 1998              (225,000)           (225)      (99,775)                 (100,000)
Issuance of 129,500 shares - Various dates in 1998                 129,500             130        18,390                    18,520
Reduction of paid in capital for management fees                                                  (8,377)                   (8,377)
Net loss for the year ended July 31, 1998                                                                    (778,556)    (778,556)
                                                             ----------------------------------------------------------------------
Balance at July 31, 1998                                         5,818,813           5,819       627,726   (1,104,236)    (470,691)
Issuance of 178,000 shares - Various dates in 1998                 178,000             178        72,372                    72,550
Repurchase of 73,000 shares - Various dates in 1998                (73,000)            (73)       (5,227)                   (5,300)
Issuance of 43,000 shares - Various dates in 1998                   43,000              43        87,442                    87,485
Reduction of paid in capital for management fees                                                 (16,215)                  (16,215)
Net loss for 5 months ended December 31, 1998                                                                (403,184)    (403,184)
                                                             ----------------------------------------------------------------------
Balance at December 31, 1998                                     5,966,813           5,967       766,098   (1,507,420)    (735,355)
Issuance of 4,576,555 shares - Various dates in 1999             4,576,555           4,576       482,296                   486,872
Net loss for the year ended December 31, 1999                                                                  57,393       57,393
                                                             ----------------------------------------------------------------------
Balance at December 31, 1999                                    10,543,368          10,543     1,248,394   (1,450,027)    (191,090)
Issuance of shares previously subscribed - various dates         4,420,783           4,421       493,512                   497,933
Issuance of shares for services rendered                           583,652             584        24,766                    25,350
Cancelation of previously issued shares                           (200,000)           (200)                                   (200)
Net loss for the year ended December 31, 2000                                                                (557,741)    (557,741)
                                                             ----------------------------------------------------------------------
Balance at December 31, 2000                                    15,347,803          15,348     1,766,672   (2,007,768)    (225,748)
Issuance of shares for cash                                        928,137             928        90,345                    91,273
Cancellation of previously issued shares                          (928,137)           (928)                                   (928)
Stock subscribed but not issued at September 30, 2001              280,000             280                                     280
Net loss for nine months ended September 30, 2001                                                            (292,871)    (292,871)
                                                             ----------------------------------------------------------------------
Balance at September 31, 2001                                   15,627,803*      $  15,628 $   1,857,017  $(2,300,639)$   (427,994)
                                                             ======================================================================

(* Post reverse split 390,696)

</TABLE>


(1) See notes to the financial statements.
(2) Stock issued in exchange for legal expenses, administrative fees and
commissions relating to the stock offering.
(3) Stock issue costs deducted from additional paid in capital related to the
offering/sale totaled $53,697.

See notes to financial statements.

                                      F-3

<PAGE>

<TABLE>
<CAPTION>

PATHOBIOTEK DIAGNOSTICS, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS (UNAUDITED)




                                                         Nine            Nine            Three           Three            From
                                                        months          months          months           months      August 5, 1996
                                                        ended            ended           ended           ended          through
                                                    Sept. 30, 2001   Sept. 30, 2000  Sept. 30, 2001  Sept. 30, 2000  Sept. 30, 2001
                                                    ---------------  --------------  --------------  --------------- ---------------
<S>                                                <C>                    <C>              <C>     <C>              <C>
OPERATING ACTIVITIES
Net loss                                           $      (292,871)$      (681,426)$       (76,150)$       (171,940)$    (2,300,639)
Adjustments to reconcile net loss to net cash
   provided by (used in) operating activities:
      Depreciation and amortization                         23,261          20,894           7,815            7,467         125,554
      Changes in operating assets and liabilities:
         Other receivables                                       0          13,185               0                0          (2,158)
         Patent costs                                            0         (14,760)              0           (1,000)        (59,459)
         Deposits                                                0         (10,000)              0          (10,000)        (10,000)
         Other assets                                            0               0               0                0            (300)
         State tax refund receivable                             0             270               0                0               0
         Trade accounts payable and accrued expenses       139,854         330,789          75,459           88,703         463,067
                                                    ---------------  --------------  --------------  --------------- ---------------
Net cash provided by (used in) operating activities       (129,756)       (341,048)          7,124          (86,770)     (1,783,935)

INVESTING ACTIVITIES
Capital expenditures                                        (2,833)        (11,172)              0           (2,194)       (145,366)
Reverse merger                                                   0               0               0                0        (150,000)
                                                    ---------------  --------------  --------------  --------------- ---------------
Net cash provided by (used in) investing activities         (2,833)        (11,172)              0           (2,194)       (295,366)

FINANCING ACTIVITIES
Cash overdraft                                               8,432               0           8,432                0           8,432
Proceeds from short-term debt                               70,000               0               0                0          70,000
Principal payments on long-term debt                             0         (40,639)              0           (7,900)        (16,054)
Related parties                                            (41,583)              0         (39,794)               0         (13,433)
Proceeds from issuance of stock                             90,625         497,933          16,490          226,073       2,030,356
                                                    ---------------  --------------  --------------  --------------- ---------------
Net cash provided by (used in) financing activities        127,474         457,294         (14,872)         218,173       2,079,301
                                                    ---------------  --------------  --------------  --------------- ---------------
(DECREASE) INCREASE IN CASH                                 (5,115)        105,074          (7,748)         129,209               0
Cash and cash equivalents at beginning of period             5,115          24,135           7,748                0               0
                                                    ---------------  --------------  --------------  --------------- ---------------
Cash and cash equivalents at end of period         $             0 $       129,209 $             0 $        129,209 $             0
                                                    ===============  ==============  ==============  =============== ===============

</TABLE>

See notes to financial statements.

F-4


<PAGE>

PATHOBIOTEK DIAGNOSTICS, INC.
(A Development Stage Company)
NOTES TO UNAUDITED FINANCIAL STATEMENTS
September  30, 2001

Note 1 - Organization and Business Activity

Pathobiotek Diagnostics, Inc., (the "Company") was formed on August 5, 1996,
under the laws of the State of Texas for the purpose of developing, producing,
distributing, selling and/or performing diagnostics for various virus and
bacterium. The Company is a developmental stage company under Statement of
Financial Accounting Standard ("SFAS") No 7, "Accounting and Reporting by
Development State Enterprises". Pathobiotek Diagnostics, Inc. was a subsidiary
of Pacific Biotech International, Inc. (the "Parent"), a Texas Corporation,
until May 16, 2000. Pacific Biotech International, Inc. no longer owns any
shares of the Company. On March 6, 2000, the Company completed a Share Purchase
Agreement with shareholders of Investra Enterprises, Inc. (IEI) in which the
Company acquired all 672,000 issued and outstanding shares of IEI for $150,000
for purposes of completing a merger of the Company and IEI. The Company was the
surviving entity. These financial statements assume the Company will continue as
a going concern. There is substantial doubt the Company can continue as a going
concern due to losses and a lack of financing. No adjustments have been made for
this uncertainty.

Note 2 - Changes in Control of Registrant

On August 24, 2001, Pathobiotek Diagnostics, Inc. and ATNG, Inc. entered into an
Agreement and Plan of Reorganization in which 100% of outstanding shares of ATNG
were  exchanged by ATNG for  27,836,186  shares of  Pathobiotek.  Upon exchange,
ATNG, Inc. became a wholly-owned subsidiary of Pathobiotek Diagnostics, Inc.

Note 3 - Other Events

On October 17, 2001, the Company changed its name to ATNG, Inc., by filing
Amendments to its Articles of Incorporation in Texas.


Note 4 - Net  (Loss) Per Share

Basic and diluted net loss per share information is presented under the
requirements of SFAS No. 128, Earnings Per Share. Basic net loss per share is
computed by dividing net loss by the weighted average number of shares of common
stock outstanding for the period, less shares subject to repurchase. Diluted net
loss per share reflects the potential dilution of securities by adding other
common stock equivalents, including stock options, shares subject to repurchase,
warrants and convertible preferred stock, in the weighted-average number of
common shares outstanding for a period, if dilutive. All potentially dilutive
securities have been excluded from the computation, as their effect is
anti-dilutive. Loss per share for the three and nine months ended September 30,
2001 was $(.01) and $(.02), respectively, and loss per share for the three and
nine-months ended September 30, 2000 was $(.01) and $(.05), respectively.


Note 5 - Reverse Stock Split

At a shareholders meeting held on July 16, 2001, the shareholders approved a one
for forty reverse split of common shares except no shareholder to be reduced to
less than ten shares. At the same meeting, shareholders approved the transfer of
technology, patents, and proprietary research to Pathobiotek, Inc., a
wholly-owned subsidiary and a spin-off by dividend, share for share (pre-reverse
split), of the subsidiary Pathobiotek, Inc. to shareholders, pro rata, effective
for shareholders as of record date of June 22, 2001.


                                      F-5


<PAGE>


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL  CONDITION AND RESULTS
OF OPERATIONS

STATEMENT OF CHANGES IN FINANCIAL CONDITION

The Company transferred all its assets in biotech related business to its wholly
owned subsidiary  Pathobiotek,  Inc., a Nevada corporation,  prior to a pro-rata
spin-off by dividend to shareholders, approved by the shareholders in July 2001.
All operations  were assumed by the  subsidiary in the quarter,  and the results
shown are those of the  discontinued  operations.  Subsequent  to period end, in
October 2001, the Company completed a Plan and Agreement of Reorganization  with
ATNG, Inc., a company in the long distance  telephone  marketing  business.  The
Company  changed  its  name  subsequent  to  quarter  end to ATNG,  Inc.  Future
operations results will be those of ATNG, Inc.

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPT. 30, 2001 COMPARED TO SEPT.
30, 2000

The  Company  discontinued  operations  in the period in  biotechnology  related
business  due to a  spin-off  to  shareholders  pro  rata  of the  wholly  owned
subsidiary Pathobiotek,  Inc. All biotech related assets were transferred to the
subsidiary prior to spin-off.

The Company is in the  development  stage and had no revenues for the nine month
period ended  September 30, 2001 but incurred  expenses  totalling  $291,901 and
interest  cost of $970.  The  expenses  for the nine  month  period in 2000 were
$678,927  plus $2,499 in interest for a total of $681,426 in  expenses.  The net
loss for the nine month period was ($292,871) in 2001 and (681,426) in 2001, and
the per share loss  was ($.02) in 2001 and ($.05) in 2000 on a pre-reverse split
basis.

The Company has had minimal  revenues  since  inception in August 1996,  but has
incurred  ($2,300,639) in deficit during the period since inception to September
30, 2000. The Company  expects the trend of losses to continue in the forseeable
future due to the start up of business.

RESULTS OF  OPERATIONS  FOR THE QUARTER  ENDED  SEPTEMBER  30, 2001  COMPARED TO
SEPTEMBER 30, 2000

The Company had no revenues in the quarter ended  September 30, 2001 or 2000 but
incurred operating expenses of $76,150 in 2001 and $171,940, including interest,
in 2000.  The Company had a net loss of (76,150) in 2001 and  ($171,940) for the
quarter in 2000.  The  Company is in the  development  stage and has had minimal
revenues since inception in August 1996.

The  Company  loss per share for the  quarter  was  ($.01) in 2001 and 2000 on a
pre-reverse split basis.  The Company expects the trend of losses to continue in
the  forseeable  future due to the lack of  developed,  marketable  products  or
technology.

LIQUIDITY AND CAPITAL RESOURCES

The Company had no cash  capital at the end of the period.  The Company  will be
forced to either  borrow or make  private  placements  of stock in order to fund
operations.  No  assurance  exists as to the  ability to  achieve  loans or make
private placements of stock.


<PAGE>


                           PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

        None

ITEM 2. CHANGES IN SECURITIES

        None

ITEM 3. DEFAULT UPON SENIOR SECURITIES

        None

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

          On July  16,  2001 a  Shareholders'  Meeting  was  held at  which  the
          shareholders approved:

          1.  A 1 for 40 reverse split of the issued and outstanding shares;

          2.  A name change in the discretion of the Board of Directors;

          3.  The spin-off pro rata of the shares of the wholly owned subsidiary
              Pathobiotek, Inc. to Company shareholders as a dividend.

ITEM 5. OTHER INFORMATION

        None

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

        8-K filed August 6, 2001

        8-K filed September 4, 2001

        8-K filed September 21, 2001



<PAGE>


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

Date: December 7, 2001

                                    PATHOBIOTEK DIAGNOSTICS, INC.



                                    /s/ E. Robert Gates
                                    --------------------------
                                    E. Robert Gates, President